Skip to main content

rina-s

rina-s: 8 clinical trials tracked.

rina-s evidence translation

What we can confirm

8 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about rina-s, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trials (8)

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

NCT07564141·Phase 3·GMAB
Recruiting

Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen688 targetStarted 2026-08Completion 2031-112 sites · United StatesGenmab

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

NCT07604766·Phase 3·GMAB
Recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen82 targetStarted 2026-06Completion 2028-1217 sites · ChinaGenmab

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

NCT07539311·Phase 2·GMAB
Recruiting

Primary endpoint: Confirmed Objective Response Rate (ORR)

Interventionalopen160 targetStarted 2026-05Completion 2028-114 sites · Japan, United StatesGenmab

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

NCT07225270·Phase 3·GMAB
Recruiting

Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen544 targetStarted 2026-04Completion 2030-0516 sites · Japan, United StatesGenmab

A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

NCT07288177·Phase 2·GMAB
Recruiting

Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator

Interventionalopen240 targetStarted 2026-01Completion 2028-1150 sites · Australia, Belgium, China, France…Genmab

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

NCT07166094·Phase 3·GMAB
Recruiting

Primary endpoint: Progression-free Survival (PFS) per Response Criteria in Solid Tumors (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen660 targetStarted 2025-11Completion 2029-1150 sites · United StatesGenmab

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

NCT06619236·Phase 3·GMAB
Active, not recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen530 targetStarted 2025-02Completion 2028-0550 sites · United StatesGenmab

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

NCT05579366·Phase 1/Phase 2·GMAB
Recruiting

Primary endpoint: Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]

Interventionalopen884 targetStarted 2022-12Completion 2027-1050 sites · China, United StatesGenmab